Sergio Ruiz-Llorente

Sergio Ruiz-Llorente

Auto-generated profile, based on publicly available information

Sergio Ruiz-Llorente

Unit of Gynecological, Genitourinary and Skin Tumors, Hospital HM Sanchinarro, Fundación Investigación HM Hospitales, Madrid, Spain

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CMCristina Montero-Conde
Cristina Montero-Conde
SRSergio Ruiz-Llorente
Sergio Ruiz-Llorente
JDJose M. Dominguez
Jose M. Dominguez
JKJeffrey A. Knauf
Jeffrey A. Knauf
AVAgnes Viale
Agnes Viale
JFJames A. Fagin
James A. Fagin
The RAF inhibitor vemurafenib (PLX4032) increases survival in patients with BRAF-mutant metastatic melanoma, but has limited efficacy in patients with colorectal cancers. Thyroid cancer cells are also comparatively refractory to RAF inhibitors. In contrast to melanomas, inhibition of mitogen-activated protein kinase (MAPK) signaling by PLX4032 is transient in thyroid and colorectal cancer cells. The rebound in extracellular signal-regulated kinase (ERK) in thyroid cells is accompanied by increased HER3 signaling caused by induction of ERBB3 (HER3) transcription through decreased promoter occupancy by the transcriptional repressors C-terminal binding protein 1 and 2 and by autocrine secretion of neuregulin-1 (NRG1). The HER kinase inhibitor lapatinib prevents MAPK rebound and sensitizes BRAF-mutant thyroid cancer cells to RAF or MAP-ERK kinase inhibitors. This provides a rationale for combining ERK pathway antagonists with inhibitors of feedback-reactivated HER signaling in this disease. The determinants of primary resistance to MAPK inhibitors vary between cancer types, due to preferential upregulation of specific receptor tyrosine kinases, and the abundance of their respective ligands. Significance: Thyroid cancer cell lines with mutant BRAF are resistant to PLX4032. RAF inhibitors transiently inhibit the ERK pathway and de-repress HER3 transcription. In the context of constitutive NRG1 secretion, this results in an ERK and AKT rebound that diminishes the antitumor effects of RAF inhibitors, which is overcome by combination with lapatinib. Cancer Discov; 3(5); 520–33. ©2013 AACR. See related commentary by Girotti and Marais, p. 487 This article is highlighted in the In This Issue feature, p. 471

4 September 2009 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
Iñigo LandaIñigo Landa
Iñigo Landa
SRSergio Ruiz-Llorente
Sergio Ruiz-Llorente
CMCristina Montero-Conde
Cristina Montero-Conde
LILucía Inglada-Pérez
Lucía Inglada-Pérez
Francesca SchiaviFrancesca Schiavi
Francesca Schiavi
MRMercedes Robledo
Mercedes Robledo
In order to identify genetic factors related to thyroid cancer susceptibility, we adopted a candidate gene approach. We studied tag- and putative functional SNPs in genes involved in thyroid cell differentiation and proliferation, and in genes found to be differentially expressed in thyroid carcinoma. A total of 768 SNPs in 97 genes were genotyped in a Spanish series of 615 cases and 525 controls, the former comprising the largest collection of patients with this pathology from a single population studied to date. SNPs in an LD block spanning the entire FOXE1 gene showed the strongest evidence of association with papillary thyroid carcinoma susceptibility. This association was validated in a second stage of the study that included an independent Italian series of 482 patients and 532 controls. The strongest association results were observed for rs1867277 (OR[per-allele] = 1.49; 95%CI = 1.30–1.70; P = 5.9×10−9). Functional assays of rs1867277 (NM_004473.3:c.−283G>A) within the FOXE1 5′ UTR suggested that this variant affects FOXE1 transcription. DNA-binding assays demonstrated that, exclusively, the sequence containing the A allele recruited the USF1/USF2 transcription factors, while both alleles formed a complex in which DREAM/CREB/αCREM participated. Transfection studies showed an allele-dependent transcriptional regulation of FOXE1. We propose a FOXE1 regulation model dependent on the rs1867277 genotype, indicating that this SNP is a causal variant in thyroid cancer susceptibility. Our results constitute the first functional explanation for an association identified by a GWAS and thereby elucidate a mechanism of thyroid cancer susceptibility. They also attest to the efficacy of candidate gene approaches in the GWAS era. Although follicular cell-derived thyroid cancer has an important genetic component, efforts in identifying major susceptibility genes have not been successful. Probably this is due to the complex nature of this disease that involves both genetic and environmental factors, as well as the interaction between them, which could be ultimately modulating the individual susceptibility. In this study, focused on genes carefully selected by their biological relation with the disease, and using more than 1,000 cases and 1,000 representative controls from two independent Caucasian populations, we demonstrate that FOXE1 is associated with Papillary Thyroid Cancer susceptibility. Functional assays prove that rs1867277 behaves as a genetic causal variant that regulates FOXE1 expression through a complex transcription factor network. This approach constitutes a successful approximation to define thyroid cancer risk genes related to individual susceptibility, and identifies FOXE1 as a key factor for its development.

1 July 2004 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
LCLucía Conde
Lucía Conde
JVJuan M. Vaquerizas
Juan M. Vaquerizas
JSJavier Santoyo
Javier Santoyo
FAFátima Al-Shahrour
Fátima Al-Shahrour
SRSergio Ruiz-Llorente
Sergio Ruiz-Llorente
JDJoaquin Dopazo
Joaquin Dopazo
We have developed a web tool, PupaSNP Finder (PupaSNP for short), for high-throughput searching for single nucleotide polymorphisms (SNPs) with potential phenotypic effect. PupaSNP takes as its input lists of genes (or generates them from chromosomal coordinates) and retrieves SNPs that could affect the conserved regions that the cellular machinery uses for the correct processing of genes (intron/exon boundaries or exonic splicing enhancers), predicted transcription factor binding sites (TFBS) and changes in amino acids in the proteins. The program uses the mapping of SNPs in the genome provided by Ensembl. Additionally, user-defined SNPs (not yet mapped in the genome) can be easily provided to the program. Also, additional functional information from Gene Ontology, OMIM and homologies in other model organisms is provided. In contrast to other programs already available, which focus only on SNPs with possible effect in the protein, PupaSNP includes SNPs with possible transcriptional effect. PupaSNP will be of significant help in studies of multifactorial disorders, where the use of functional SNPs will increase the sensitivity of identification of the genes responsible for the disease. The PupaSNP web interface is accessible through http://pupasnp.bioinfo.cnio.es.

28 October 2005 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
Alberto CasconAlberto Cascon
Alberto Cascon
CMCristina Montero-Conde
Cristina Montero-Conde
SRSergio Ruiz‐Llorente
Sergio Ruiz‐Llorente
FMFátima Mercadillo
Fátima Mercadillo
RLRocío Letón
Rocío Letón
MRMercedes Robledo
Mercedes Robledo

8 September 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VGVerónica García-Carpizo
Verónica García-Carpizo
JSJacinto Sarmentero
Jacinto Sarmentero
BHBomie Han
Bomie Han
OGOsvaldo Graña
Osvaldo Graña
SRSergio Ruiz-Llorente
Sergio Ruiz-Llorente
MBMaria J. Barrero
Maria J. Barrero
The histone methyltransferase NSD2/WHSC1/MMSET is overexpressed in a number of solid tumors but its contribution to the biology of these tumors is not well understood. Here, we describe that NSD2 contributes to the proliferation of a subset of lung cancer cell lines by supporting oncogenic RAS transcriptional responses. NSD2 knock down combined with MEK or BRD4 inhibitors causes co-operative inhibitory responses on cell growth. However, while MEK and BRD4 inhibitors converge in the downregulation of genes associated with cancer-acquired super-enhancers, NSD2 inhibition affects the expression of clusters of genes embedded in megabase-scale regions marked with H3K36me2 and that contribute to the RAS transcription program. Thus, combinatorial therapies using MEK or BRD4 inhibitors together with NSD2 inhibition are likely to be needed to ensure a more comprehensive inhibition of oncogenic RAS-driven transcription programs in lung cancers with NSD2 overexpression.

16 July 2002 in European Journal of Human Genetics
Verified
Journal Article
Closed access
Alberto CasconAlberto Cascon
Alberto Cascon
SRSergio Ruiz-Llorente
Sergio Ruiz-Llorente
Arancha CebriánArancha Cebrián
Arancha Cebrián
DTDolores Telleria
Dolores Telleria
JRJose Carlos Rivero
Jose Carlos Rivero
MRMercedes Robledo
Mercedes Robledo